Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia. Klink AJ, Gajra A, Knoth RL, Marshall L, et al. Leuk Res 2022;122:106946.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Klink AJ, Gajra A, Knoth RL, Marshall L, et al. Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia. Leuk Res 2022;122:106946.
PMID: 36108427